Metformin and Thyroid: An Update
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is one of the most widely prescribed antidiabetic medications with a favorable safety profile. In the last decade, several studies have reported a TSH-lowering effect of metformin in patients with diabetes mellitus. OBJECTIVE: To review literature data on the role of metformin use on thyroid function tests and the course of thyroid cancer. METHODS: WE PERFORMED A SEARCH IN THE PUBMED DATABASE USING THE TERMS: 'metformin', 'thyroid', 'TSH', 'diabetes', 'polycystic ovarian syndrome (PCOS)' and 'thyroid cancer'. RESULTS: The majority of available evidence suggests that metformin therapy results in a modest reduction of TSH levels in diabetic and/or PCOS patients with thyroid disorder, while thyroid hormone levels remain unaltered. It appears that this effect is independent of thyroid autoimmunity and thyroxine treatment. However, metformin use in subjects with an intact thyroid axis is not associated with a significant change of TSH levels. Concerning thyroid cancer, there is experimental evidence showing antimitogenic properties of metformin in differentiated and medullary thyroid cancer cells. On the other hand, there is also data supporting that metformin administration inhibits iodine uptake by thyroid cells and thus may limit the effectiveness of radioactive iodine treatment. CONCLUSIONS: Most studies suggest a TSH suppressive action of metformin in subjects with overt or subclinical thyroid dysfunction, while this is not apparent in euthyroid individuals. It appears that metformin has antimitogenic properties against various thyroid cancer types; however, experimental evidence of reduced efficacy of radioactive iodine treatment following metformin administration may limit its use in the management of differentiated thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Knudsen, N., Laurberg, P., Rasmussen, L. B., Bülow, I., Perrild, H., Ovesen, L., & Jørgensen, T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2225 · Cited by 753
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Chen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196
Thyrotropin Suppression by Metformin
Vigersky, R. A., Filmore-Nassar, A., & Glass, A. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1210 · Cited by 174
TSH-Lowering Effect of Metformin in Type 2 Diabetic Patients
Cappelli, C., Rotondi, M., Pirola, I., Agosti, B., Gandossi, E., Valentini, U., De Martino, E., Cimino, A., Chiovato, L., Agabiti-Rosei, E., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0273 · Cited by 173
Chubb, S. A. P., Davis, W. A., Inman, Z., & Davis, T. M. E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02246.x · Cited by 143
Kok, P., Roelfsema, F., Langendonk, J. G., Frölich, M., Burggraaf, J., Meinders, A. E., & Pijl, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0920 · Cited by 132
Isidro, M. L., Penín, M. A., Nemiña, R., & Cordido, F. (2007) · Endocrine · doi:10.1007/s12020-007-9012-3 · Cited by 93
Cited by
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Metformin does not suppress serum thyrotropin by increasing levothyroxine absorption
Al-Alusi, M. A., Du, L., Li, N., Yeh, M. W., He, X., Braverman, L. E., & Leung, A. M. (2015) · Thyroid · doi:10.1089/thy.2015.0211 · Cited by 14
Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses
Li, H., Chen, Y., Hu, L., Yang, W., Gao, Z., Liu, M., Tao, H., & Li, J. (2023) · European Journal of Medical Research · doi:10.1186/s40001-023-01287-0 · Cited by 10
“AMPK can also induce catabolism and downregulate cell proliferation by mimicking a state of caloric deprivation, mechanisms that have been associated with metforminmediated inhibition of cancer cell growth [51].”
Background
Metadata
- Authors
- Pappa, T., & Alevizaki, M.
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2013
- Volume
- 2
- Issue
- 1
- Pages
- 22-28
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- OpenAlex
- W2126877148
- Cited by
- 48
- References
- 10
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.